Stryker had its Relative Strength (RS) Rating upgraded from 75 to 83 Thursday.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Stryker is building a consolidation with a 406.19 entry. See if it can break out in heavy volume.
Stryker reported 16% EPS growth in the latest quarterly report, while sales growth came in at 11%. Keep an eye out for the company's next round of numbers on or around May 1.
Stryker earns the No. 10 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
